NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
December 12, 2022 19:00 ET
|
NGM Biopharmaceuticals, Inc.
--NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells while inducing minimal cytokine release in preclinical...
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
December 07, 2022 18:45 ET
|
NGM Biopharmaceuticals, Inc.
NGM707 was generally well tolerated to the highest dose evaluated (1800 mg) in the monotherapy escalation; maximum tolerated dose was not reachedLinear pharmacokinetics (PK) was observed at doses ≥200...
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
November 07, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
Poster presentation to showcase initial data from the Phase 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in...
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
November 04, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
--Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T...
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
November 03, 2022 16:05 ET
|
NGM Biopharmaceuticals, Inc.
--Announced that the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration did not meet primary endpoint of statistically significant rate...
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
November 03, 2022 13:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
October 17, 2022 07:30 ET
|
NGM Biopharmaceuticals, Inc.
Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus shamNGM621 showed favorable safety and...
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
October 16, 2022 16:30 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00...
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer
September 13, 2022 17:30 ET
|
NGM Biopharmaceuticals, Inc.
NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancerNGM120 has been well tolerated to date in patients in the Phase 1b combination...
NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress
September 06, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancerNGM120 has been well tolerated to date in patients in the Phase 1a study with...